Monoclonal antibody reduces asthma attacks in urban youth

A National Institutes of Health clinical trial has found that a monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of severe asthma, are prone to asthma attacks and live in low-income urban neighborhoods. This population has been underrepresented in previous clinical trials of asthma therapeutics. The findings were published today in the journal The Lancet.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup